Cargando…

Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma

BACKGROUND: Cholangiocarcinoma (CCA) is one of the most fatal malignant tumors with increasing incidence, mortality, and insensitivity to traditional chemo-radiotherapy and targeted therapy. Chimeric antigen receptor-modified T cell (CART) immunotherapy represents a novel strategy for the management...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Kai-chao, Guo, Ye-lei, Liu, Yang, Dai, Han-ren, Wang, Yao, Lv, Hai-yan, Huang, Jian-hua, Yang, Qing-ming, Han, Wei-dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217546/ https://www.ncbi.nlm.nih.gov/pubmed/28057014 http://dx.doi.org/10.1186/s13045-016-0378-7

Ejemplares similares

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
por: Dai, Hanren, et al.
Publicado: (2016)

Fully human CD19-specific chimeric antigen receptors for T-cell therapy
por: Sommermeyer, Daniel, et al.
Publicado: (2017)

Chimeric antigen receptor modified T-cells for cancer treatment
por: Han, Xiao, et al.
Publicado: (2018)

Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials
por: Jena, Bipulendu, et al.
Publicado: (2013)

CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma
por: Fan, Linni, et al.
Publicado: (2011)

Programmed death‐ligand 1 expression on CD22‐specific chimeric antigen receptor‐modified T cells weakens antitumor potential
por: Liu, Jie, et al.
Publicado: (2022)

CD133 antigen expression in ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2009)

Isolation, identification and expression of specific human CD133 antibodies
por: Xia, Jing, et al.
Publicado: (2013)

Lessons learned from a highly-active CD22-specific chimeric antigen receptor
por: Long, Adrienne H., et al.
Publicado: (2013)

The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing
por: Riberdy, Janice M., et al.
Publicado: (2020)

miR-451 Up-regulation, Induce Erythroid Differentiation of CD133+cells Independent of Cytokine Cocktails
por: Kouhkan, Fatemeh, et al.
Publicado: (2013)

GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients
por: Yu, Lihua, et al.
Publicado: (2021)

Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report
por: Zhang, Wen-ying, et al.
Publicado: (2016)

Utilizing induced neural stem cell‐based delivery of a cytokine cocktail to enhance chimeric antigen receptor‐modified T‐cell therapy for brain cancer
por: Woodell, Alex S., et al.
Publicado: (2023)

4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2(nd) Generation Chimeric Antigen Receptor-Modified T Cells
por: Dai, Qiang, et al.
Publicado: (2020)

Polymorphic Region-Specific Antibody for Evaluation of Affinity-Associated Profile of Chimeric Antigen Receptor
por: Han, Chungyong, et al.
Publicado: (2020)

CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
por: Wang, Yao, et al.
Publicado: (2018)

Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
por: Guo, Yelei, et al.
Publicado: (2016)

Preclinical efficacy and toxicity studies of a highly specific chimeric anti‐CD47 antibody
por: Xu, Zhiqiang, et al.
Publicado: (2021)

CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations
por: Tang, Ling, et al.
Publicado: (2022)

GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma – assessing tumor and T cell interaction
por: Sujjitjoon, Jatuporn, et al.
Publicado: (2020)

Chimeric antigen-guiding extracellular vesicles eliminate antigen-specific Th2 cells in subjects with food allergy
por: Zhang, Yuan-Yi, et al.
Publicado: (2021)

Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
por: Pang, Yanyu, et al.
Publicado: (2018)

Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells
por: Chmielewski, Markus, et al.
Publicado: (2013)

CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells
por: Li, Guangchao, et al.
Publicado: (2021)

Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma
por: Supimon, Kamonlapat, et al.
Publicado: (2021)

Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
por: Wang, Zhenguang, et al.
Publicado: (2017)

Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients
por: Zhang, Mingyu, et al.
Publicado: (2008)

Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
por: Ying, Zhitao, et al.
Publicado: (2021)

Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma
por: Sangsuwannukul, Thanich, et al.
Publicado: (2022)

Chimeric Murine Polyomavirus Virus-Like Particles Induce Plasmodium Antigen-Specific CD8(+) T Cell and Antibody Responses
por: Pattinson, David J., et al.
Publicado: (2019)

A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer
por: Yong, Carmen S.M., et al.
Publicado: (2016)

Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells
por: Singh, Harjeet, et al.
Publicado: (2013)

CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma
por: Cai, Xiaobo, et al.
Publicado: (2018)

Computational Model of Chimeric Antigen Receptors Explains Site-Specific Phosphorylation Kinetics
por: Rohrs, Jennifer A., et al.
Publicado: (2018)

Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies
por: Dabiri, Hamed, et al.
Publicado: (2023)

Use of Chimeric Antigen Receptor Modified T Cells With Extensive Leukemic Myocardial Involvement
por: Han, Brian, et al.
Publicado: (2020)

Therapeutic efficacy and infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy
por: Gao, Zhilin, et al.
Publicado: (2023)

Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma
por: Tseng, Hsiang-chi, et al.
Publicado: (2020)

Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy
por: Hu, Sheng-I, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9v8iqnvna56ro1hnj341ven3i7